Orthobiologics Market Global Industry Trends and Revenue Analysis 2034
Orthobiologics Market Global Industry Trends and Revenue Analysis 2034
The Orthobiologics share in 2026 are biological products used in orthopedic procedures to support the healing of bones, muscles, ligaments, and tendons. These products are often made from substances naturally found in the body and are used to improve the healing of injuries and bone defects. Growing orthopedic disorders, trauma, fractures, osteoporosis, and sports injuries are increasing the need for these products.
According to Fortune Business Insights, the global orthobiologics market size was valued at USD 9.7 billion in 2025. North America dominated the market with a 47.69% share in 2025, supported by the rapid adoption of biologics for bone-related injuries and disorders, rising orthopedic surgeries, and product launches.
The increasing prevalence of orthopedic injuries and musculoskeletal diseases is a major factor supporting market growth. According to the report, more than 6.8 million patients with orthopedic injuries receive medical attention every year in the U.S. The rising incidence of osteoporosis is also contributing to hip and backbone fractures, while road accidents and sports injuries increase the use of orthobiologics in orthopedic procedures.
Product innovation is another important growth factor. Market players are introducing allografts, bone growth factors, synthetic bone substitutes, and bone void fillers. The report highlights product launches and approvals involving cellular bone allografts, synthetic grafts, and antibiotic-mixing applications for bone void fillers.
The increasing use of viscosupplements is another market trend. Viscosupplements are used for osteoarthritis and can help improve the properties of synovial fluid, joint function, and cartilage recovery. Their adoption has increased due to their potential role in delaying total knee replacement procedures.
However, clinical limitations and concerns associated with some orthobiologics can restrict market expansion. The report highlights concerns related to bone morphogenetic proteins, including complications associated with INFUSE. Bone graft substitutes may also face limitations such as adverse tissue reactions, incomplete bone formation, and infection of soft tissue and bone.
The competitive landscape is fragmented, with leading companies maintaining significant positions through broad product portfolios and strategic initiatives. Medtronic, DePuy Synthes, Zimmer Biomet, and Stryker are among the major players identified in the report. Medtronic held a significant position due to its strong portfolio of bone graft substitutes and focus on expanding its geographic footprint.
Recent developments cited by Fortune Business Insights include OsteoCove by Orthofix Medical, Tactoset clearance received by Anika Therapeutics, ViviGen MIS launched by LifeNet Health, and collaborations involving MTF Biologics and Bone Biologics.
Medtronic (Ireland)
Zimmer Biomet (U.S.)
DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.)
Stryker (U.S.)
Anika Therapeutics, Inc. (U.S.)
SeaSpine (U.S.)
Bioventus (U.S.)
RTI Surgical (U.S.)
MTF Biologics (U.S.)
Arthrex, Inc. (U.S.)
Smith & Nephew (U.K.)
By Product Type (Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Cellular Allograft, Allografts, and Others)
By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery, and Others)
By End-user (Hospitals & ASCs, Specialty Clinics, and Others
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173
North America held the largest market share of 47.69% in 2025, with a market value of USD 4.63 billion. The regional market is projected to reach USD 4.87 billion in 2026.
Europe generated USD 2.71 billion in 2025 and accounted for 27.94% of total market revenue. The regional market is projected to reach USD 2.84 billion in 2026. Germany and the U.K. are also important markets, with projected 2026 values of USD 0.75 billion and USD 0.53 billion, respectively.
Asia Pacific contributed USD 1.77 billion in 2025 and accounted for an 18.28% share. The market is expected to reach USD 1.89 billion in 2026 and is anticipated to record the highest CAGR among regions. Japan, China, are projected to reach USD 0.72 billion, USD 0.55 billion
Latin America generated USD 0.36 billion in 2025 and is projected to reach USD 0.38 billion in 2026. The Middle East & Africa accounted for 2.39% of global revenue in 2025 and is projected to reach USD 0.24 billion in 2026.
The orthobiologics market is expected to progress through increasing adoption of biological products, continued product launches, growing orthopedic procedures, and expanding applications. The increasing prevalence of orthopedic disorders, reconstructive surgeries, spinal procedures, fractures, and sports injuries is expected to support demand. Product development in synthetic bone substitutes, cellular allografts, bone growth factors, and other solutions can further expand application opportunities.
As companies continue to introduce new products and pursue strategic collaborations, the market is expected to maintain steady growth through 2034. Key industry developments highlighted in the report include Orthofix Medical’s launch and clearance of OsteoCove, Anika Therapeutics’ additional 510(k) clearance for Tactoset, LifeNet Health’s U.S. launch of ViviGen MIS, and partnerships supporting the development and commercialization of orthobiologic products for orthopedic and spinal applications and continued clinical adoption worldwide.
What Everyone Should Know About Japan’s Market -Orthobiologics Market- Insights